The effect of riboflavin and ultraviolet light on the infectivity of arboviruses

Transfusion

Volumn 55, Issue 4, 2015, Pages 824-831

  Faddy, Helen M ^a   Prow, Natalie A ^b   Fryk, Jesse J ^a   Hall, Roy A ^b   Keil, Shawn D ^c   Goodrich, Raymond P ^c   Marks, Denese C ^a  

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Terumo BCT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RIBOFLAVIN; PHOTOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARBOVIRUS; ARTICLE; BARMAH FOREST VIRUS; CONTROLLED STUDY; MURRAY VALLEY ENCEPHALITIS VIRUS; NONHUMAN; PATHOGEN REDUCTION SYSTEM; QUALITY CONTROL; RELATIVE DENSITY; ROSS RIVER ALPHA VIRUS; THROMBOCYTE COUNT; ULTRAVIOLET RADIATION; VERO CELL LINE; VIRUS INFECTIVITY; VIRUS REPLICATION; ADULT; ANIMAL; ARBOVIRUS INFECTIONS; AUSTRALIA; BLOOD BUFFY COAT; BLOODBORNE BACTERIUM; CHLOROCEBUS AETHIOPS; CYTOLOGY; CYTOPATHOGENIC EFFECT; DRUG EFFECTS; EVALUATION STUDY; HUMAN; PHYSIOLOGY; RADIATION RESPONSE; THROMBOCYTE; TRANSMISSION; VIROLOGY; VIRUS INACTIVATION;

ADULT; ANIMALS; ARBOVIRUS INFECTIONS; ARBOVIRUSES; AUSTRALIA; BLOOD BUFFY COAT; BLOOD PLATELETS; BLOOD-BORNE PATHOGENS; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; HUMANS; PHOTOSENSITIZING AGENTS; RIBOFLAVIN; ULTRAVIOLET RAYS; VERO CELLS; VIRUS INACTIVATION; VIRUS REPLICATION;

EID: 84926435693     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12899     Document Type: Article

References (59)

1. Dunstan RA, Seed CR, Keller AJ,. Emerging viral threats to the Australian blood supply. Aust N Z J Public Health 2008; 32: 354-360.
2. Petersen LR, Busch MP,. Transfusion-transmitted arboviruses. Vox Sang 2010; 98: 495-503.
3. Montgomery SP, Brown JA, Kuehnert M, et al. Transfusion-associated transmission of West Nile virus, United States 2003 through 2005. Transfusion 2006; 46: 2038-2046.
4. Alter HJ, Stramer SL, Dodd RY,. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007; 44: 32-41.
5. Dodd RY,. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol 2012; 159: 135-142.
6. Faddy HM, Seed CR, Fryk JJ, et al. Implications of dengue outbreaks for blood supply, Australia. Emerg Infect Dis 2013; 19: 787-789.
7. Knope K, Whelan P, Smith D, et al. Arboviral diseases and malaria in Australia, 2010-11: annual report of the National Arbovirus and Malaria Advisory Committee. Commun Dis Intell Q Rep 2013; 37: E1-20.
8. Gould EA, Higgs S,. Impact of climate change and other factors on emerging arbovirus diseases. Trans R Soc Trop Med Hyg 2009; 103: 109-121.
9. Williams S, Richards J, Faddy H, et al. Opportunistic seroprevalence study for Murray Valley encephalitis and Kunjin viruses in Victoria, Australia 2011. Aust N Z J Public Health 2013; 37: 427-433.
10. Semenza JC, Domanovic D,. Blood supply under threat. Nat Clim Change 2013; 3: 432-435.
11. Kay BH, Boyd AM, Ryan PA, et al. Mosquito feeding patterns and natural infection of vertebrates with Ross River and Barmah Forest viruses in Brisbane, Australia. Am J Trop Med Hyg 2007; 76: 417-423.
12. Old JM, Deane EM,. Antibodies to the Ross River virus in captive marsupials in urban areas of eastern New South Wales, Australia. J Wildl Dis 2005; 41: 611-614.
13. Jansen CC, Prow NA, Webb CE, et al. Arboviruses isolated from mosquitoes collected from urban and peri-urban areas of eastern Australia. J Am Mosq Control Assoc 2009; 25: 272-278.
14. Chapman HF, Hughes JM, Jennings C, et al. Population structure and dispersal of the saltmarsh mosquito Aedes vigilax in Queensland, Australia. Med Vet Entomol 1999; 13: 423-430.
15. Hu W, Tong S, Mengersen K, et al. Mosquito species (Diptera: Culicidae) and the transmission of Ross River virus in Brisbane, Australia. J Med Entomol 2006; 43: 375-381.
16. Robertson GJ, Doggett S, Seeman O, et al. Ross River virus and its vectors in Sorell Municipal Area, south-eastern Tasmania, January to March 2002. Commun Dis Intell 2004; 28: 261-266.
17. Mackenzie JS, Smith DW,. Mosquito-borne viruses and epidemic polyarthritis. Med J Aust 1996; 164: 90-93.
18. Aaskov JG, Chen JY, Hanh NT, et al. Surveillance for Ross River virus infection using blood donors. Am J Trop Med Hyg 1998; 58: 726-730.
19. Harley D, Sleigh A, Ritchie S,. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 2001; 14: 909-932.
20. Fraser JR, Cunningham AL,. Incubation time of epidemic polyarthritis. Med J Aust 1980; 1: 550-551.
21. Herrero LJ, Lidbury BA, Bettadapura J, et al. Characterization of Barmah Forest virus (BFV) pathogenesis in a mouse model. J Gen Virol 2014; 95: 2146-2154.
22. Jacups SP, Whelan PI, Currie BJ,. Ross River virus and Barmah Forest virus infections: a review of history, ecology, and predictive models, with implications for tropical northern Australia. Vector Borne Zoonotic Dis 2008; 8: 283-297.
23. Gatton ML, Kay BH, Ryan PA,. Environmental predictors of Ross River virus disease outbreaks in Queensland, Australia. Am J Trop Med Hyg 2005; 72: 792-799.
24. Tong S, Hu W, McMichael AJ,. Climate variability and Ross River virus transmission in Townsville Region, Australia, 1985-1996. Trop Med Int Health 2004; 9: 298-304.
25. Jacups SP, Whelan PI, Harley D,. Arbovirus models to provide practical management tools for mosquito control and disease prevention in the Northern Territory, Australia. J Med Entomol 2011; 48: 453-460.
26. Mackenzie JS, Broom AK, Hall RA, et al. Arboviruses in the Australian region, 1990 to 1998. Commun Dis Intell 1998; 22: 93-100.
27. Prow NA, May FJ, Westlake DJ, et al. Determinants of attenuation in the envelope protein of the flavivirus Alfuy. J Gen Virol 2011; 92: 2286-2296.
28. Knox J, Cowan RU, Doyle JS, et al. Murray Valley encephalitis: a review of clinical features, diagnosis and treatment. Med J Aust 2012; 196: 322-326.
29. Anderson SG, Eagle M,. Murray Valley encephalitis; the contrasting epidemiological picture in 1951 and 1952. Med J Aust 1953; 1: 478-481.
30. Broom AK, Lindsay MD, Plant AJ, et al. Epizootic activity of Murray Valley encephalitis virus in an aboriginal community in the southeast Kimberley region of Western Australia: results of cross-sectional and longitudinal serologic studies. Am J Trop Med Hyg 2002; 67: 319-323.
31. Smith DW, Speers DJ, Mackenzie JS,. The viruses of Australia and the risk to tourists. Travel Med Infect Dis 2011; 9: 113-125.
32. Shang G, Seed CR, Gahan ME, et al. Duration of Ross River viraemia in a mouse model-implications for transfusion transmission. Vox Sang 2012; 102: 185-192.
33. Faddy H, Dunford M, Seed C, et al. An evidence-based evaluation of the risk posed by Ross River virus to the safety of the Australian blood supply. Vox Sang 2012; 103 (Special Issue: S1 Supplement 1): 184-185.
34. Naish S, Mengersen K, Hu W, et al. Forecasting the future risk of Barmah Forest virus disease under climate change scenarios in Queensland, Australia. Plos ONE 2013; 8: e62843.
35. Marks D, Faddy H, Johnson L,. Pathogen reduction technologies. ISBT Sci Ser 2014; 9: 44-50.
36. Marschner S, Goodrich R,. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38: 8-18.
37. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-885.
38. Vanlandingham DL, Keil SD, Horne KM, et al. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013; 53: 284-290.
39. Faddy H, Fryk J, Young P, et al. The effect of pathogen reduction technology (Mirasol) on the infectivity of dengue viruses. Vox Sang 2012; 103 (Special Issue: S1 Supplement 1): 191.
40. Johnson L, Winter KM, Reid S, et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101: 208-214.
41. Clark DC, Lobigs M, Lee E, et al. In situ reactions of monoclonal antibodies with a viable mutant of Murray Valley encephalitis virus reveal an absence of dimeric NS1 protein. J Gen Virol 2007; 88: 1175-1183.
42. Hall RA, Burgess GW, Kay BH,. Type-specific monoclonal antibodies produced to proteins of Murray Valley encephalitis virus. Immunol Cell Biol 1988; 66 (Pt 1): 51-56.
43. Styer LM, Lim PY, Louie KL, et al. Mosquito saliva causes enhancement of West Nile virus infection in mice. J Virol 2011; 85: 1517-1527.
44. Burt FJ, Rolph MS, Rulli NE, et al. Chikungunya: a re-emerging virus. Lancet 2012; 379: 662-671.
45. Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007; 370: 1840-1846.
46. Dupont-Rouzeyrol M, Caro V, Guillaumot L, et al. Chikungunya virus and the mosquito vector Aedes aegypti in New Caledonia (South Pacific Region). Vector Borne Zoonotic Dis 2012; 12: 1036-1041.
47. Lanciotti RS, Roehrig JT, Deubel V, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999; 286: 2333-2337.
48. Viennet E, Knope K, Faddy H, et al. Assessing the threat of chikungunya virus emergence in Australia. Commun Dis Intell 2013; 37: E136-143.
49. Tesh RB, McLean RG, Shroyer DA, et al. Ross River virus (Togaviridae: Alphavirus) infection (epidemic polyarthritis) in American Samoa. Trans R Soc Trop Med Hyg 1981; 75: 426-431.
50. Scrimgeour EM, Aaskov JG, Matz LR,. Ross River virus arthritis in Papua New Guinea. Trans R Soc Trop Med Hyg 1987; 81: 833-834.
51. Farrugia A,. Globalisation and blood safety. Blood Rev 2009; 23: 123-128.
52. Faddy H, Seed C, Lau C, et al. Antibodies to Leptospira among blood donors in higher-risk areas of Australia: possible implications for transfusion safety. Blood Transfus 2014: 1-5.
53. Rasongles P, Angelini-Tibert MF, Simon P, et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009; 49: 1083-1091.
54. Petersen LR, Epstein JS,. Chikungunya virus: new risk to transfusion safety in the Americas. Transfusion 2014; 54: 1911-1915.
55. Faddy HM, Seed CR, Faddy MJ, et al. Malaria antibody persistence correlates with duration of exposure. Vox Sang 2013; 104: 292-298.
56. Keil SD, Kiser P, Sullivan JJ, et al. Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013; 53: 2278-2286.
57. Busch MP, Wright DJ, Custer B, et al. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis 2006; 12: 395-402.
58. Jansen CC, Ritchie SA, van den Hurk AF,. The role of Australian mosquito species in the transmission of endemic and exotic West Nile virus strains. Int J Environ Res Public Health 2013; 10: 3735-3752.
59. Custer B, Agapova M, Martinez RH,. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010; 50: 2461-2473.